- First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter studyLi, J.; Youguo, C.; Mian, H.; Chen, X.; Wen, H.; Kang, Y.; Liu, K. J.; Lou, G.; Wang, X.; Wen, Q. L.; Wang, L.; Lin, Z.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)Wu, X.; Liu, J.; Wang, L.; Lin, Z.; Wang, J.; Wang, C.; Kong, B.; Liang, Z.; Cheng, Y.; Wen, H.; Lou, G.; Huang, Y.; Wang, K.; An, R.; Zhu, J.; Zhou, H.; Yue, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebocontrolled, phase III trialWu, X.; Liu, J.; Wang, X.; Wang, J.; Wang, L.; Zhu, J.; Kong, B.; Fei, J.; Tang, Y.; Xia, B.; Liang, Z.; Wang, K.; Lin, Z.; Huang, Y.; Zheng, H.; Lin, A.; Jiang, K.; Wang, W.; Wang, X.; Lou, G.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.
3阅读
